"The decision by the NIH to fund this important gene expression research at the University of Pittsburgh represents a critical step for WaferGen and our SmartChip platform. We are pleased by the decision made by our collaborators at the University of Pittsburgh to involve the SmartChip Real- Time PCR System in novel gene expression research projects," stated Alnoor Shivji, WaferGen's chairman and chief executive officer. "The work related to the development and use of the PulmoSmartChip is particularly exciting as it will seek to demonstrate the inherent power of the SmartChip system in creating and utilizing custom disease-specific gene expression assays. We anticipate that this cutting-edge functionality, which we believe is reproducible and applicable across all disease areas, will position the SmartChip system as the platform of choice for discovery and validation of biomarkers."
The University of Pittsburgh is the first research institution to have access to WaferGen's SmartChip Real-Time PCR System. This group is a key partner for WaferGen as it oversees leading clinical and research programs in all major lung diseases including COPD, IPF and asthma. These represent just a few of the important disease indications for which the SmartChip Real-Time PCR system can enable critical gene expression research.
About the SmartChip Real-Time PCR System
The SmartChip Real-Time PCR System(TM) is designed as the first whole
genome, high-throughput gene expression real-time PCR platform. This
innovative system, combined with next-generation chemistry and optimized
assays being developed by WaferGen, promises to deliver significant speed
and cost advantages to researchers in the gene expression and genotyping
markets. Based on collaborations established with leading research
institutions, WaferGen believes that the SmartChip Real-Time PCR System is
Copyright©2008 PR Newswire.
All rights reserved